🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

Gonorrhoea infections are on the rise around the world, with figures suggesting over 82 million new cases annually. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, the spread of superbugs and the highly restricted therapeutic options currently available.”

Medical experts are increasingly worried about the rise in treatment-resistant strains. The WHO has listed it as a "high-priority threat". Ongoing monitoring found that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This approval marks a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

Based on data detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which involves an injection and a pill. The trial included nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the ability to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have shared hope. Access to a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for people and to stop the proliferation of extremely resistant gonorrhoea worldwide.